Benzinga | Jul 21, 2020 07:42AM EDT

Alliance Global Partners Initiates Coverage On Eyegate Pharmaceuticals with Buy Rating, Announces Price Target of $9.5

Alliance Global Partners analyst Ben Haynor initiates coverage on Eyegate Pharmaceuticals (NASDAQ:EYEG) with a Buy rating and announces Price Target of $9.5.